SGS Expands Viral Challenge Testing Facility
SGS has added a 12-bed, Biosafety Level 2-Q compliant, quarantine facility for viral challenge studies to its clinical pharmacology unit in Antwerp, Belgium.
SGS has added a 12-bed, Biosafety Level 2-Q compliant, quarantine facility for viral challenge studies to its clinical pharmacology unit in Antwerp, Belgium.
The Viral Challenge Testing facility features a negative pressure system with individual compartments for infected volunteers. A dedicated laboratory is equipped with a flow cabinet, acid cabinet, dedicated workspace and workflows to handle specific (viral) cultures, using HEPA-filtering and an airlock system.
“This unique, European viral challenge testing facility enhances SGS’s service offering for our clients in the fields of infectious disease and vaccine development, allowing clients a chance to improve screening and development of their compounds,” says Steven Ramael, SGS Life Science Services medical director in the announcement.
“Although the model does not necessarily reflect all parameters relevant to community-acquired infection, it does provide for a carefully controlled, systematic, and efficient method in which a number of variables can be controlled or even eliminated, with the subjects continuously monitored in a sequestered environment that minimizes safety risks for infected volunteers and that protects the outside world from a possible spread of infection,” Ramael adds.
SGS reports that this model enables detailed assessment of immune parameters that help in identifying immunological correlations of infection and illness. The sample size required to obtain meaningful results with this model is substantially lower than for community-based studies of naturally acquired infection, which can translate into savings in the clinical development costs for new vaccines or antiviral agents, according to a company statement.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
